---
title: Revised Regulatory Framework for Clinical Trials
permalink: /ct-framework/
variant: tiptap
description: ""
third_nav_title: Research Regulations
---
<p><strong>Revised Regulatory Framework for Clinical Trials</strong>
</p>
<p><strong><em>Disclaimer: Readers are advised to refer to Singapore Statues Online Website, HSA website for the latest information related to Clinical Trials, regulations and HSA Clinical Trial Regulatory Guidance.​</em></strong>
</p>
<p><strong>IMPORTANT NOTICE: [HSA Clinical Trials] UPDATES ON THE AMENDMENTS TO THE HEALTH PRODUCTS (Clinical Trials) REGULATIONS AND THE HEALTH PRODUCTS (Clinical Research&nbsp;Materials) REGULATIONS (1 OCTOBER 2021)</strong>
</p>
<p><strong><u>1. Informed Consent Requirements for the Collection of Human Tissue from Trial Participants</u></strong>
</p>
<p>To safeguard the rights, safety and well-being of trial participants,
the Health Products (Clinical Trials) Regulations has been amended. Effective
1 Oct 2021, specific additional information must be provided to trial participants
prior to obtaining consent for the collection of human tissue for the purposes
of the clinical trial.&nbsp;</p>
<p>For more information, download a copy of the HPA regulations from <strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://sso.agc.gov.sg/SL/HPA2007-S332-2016</u></a></strong>
</p>
<p>Correspondingly, the Clinical Trial Guidance “Consent Requirements for
Clinical Trials Involving Collection of Human Tissue” had been updated
(version 1 Oct 2021) and can be downloaded from&nbsp;<strong><a href="https://www.hsa.gov.sg/clinical-trials/regulatory-guidances" rel="noopener noreferrer nofollow" target="_blank"><u>HSA | Guidance documents for clinical trials</u></a></strong>.</p>
<p><strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/002f0002-b57a-48da-bfc2-380d478882c8/Additional+Reading_HSA_CT_Regulations_Consent_Req_for_HT_Collect_FINAL_22Oct21.pdf?MOD=AJPERES&amp;CVID=nRlME0i&amp;CVID=nRlME0i&amp;CVID=nRlME0i&amp;CVID=nRlME0i&amp;CVID=nRlME0i&amp;CVID=nRlME0i&amp;CVID=nRlME0i" rel="noopener noreferrer nofollow" target="_blank"><u>Additional Reading_HSA CT Regulations (Consent Req for HT Collection)</u></a></strong>
</p>
<p>&nbsp;</p>
<p><strong><u>2. Enabling Pharmacist to be Principal Investigators of Clinical Trials of Locally Registered Therapeutic Products</u></strong>
</p>
<p>The Health Products (Clinical Trials) Regulations has also been amended
to enable pharmacists to be principal investigators of clinical trials
of locally registered therapeutic products, subject to certain safeguards
and requirements. These safeguards and requirements are detailed in the
“Guidance for Pharmacist Principal Investigator” issued by the Chief Pharmacist’s
Office, MOH. The guidance can be downloaded from the MOH website.&nbsp;</p>
<p>For more information, download a copy of the Regulations from <strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://sso.agc.gov.sg/SL/HPA2007-S332-2016</u></a></strong>
</p>
<p>For more information, download a copy of the guidance from <strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://www.moh.gov.sg/hpp/pharmacists/guidelines</u></a></strong>.</p>
<p><strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/037369d0-466a-493c-81ff-cd68ca1e50aa/Health+Products+%28Clinical+Trials%29+Regulations+2016+%281%29.pdf?MOD=AJPERES&amp;CVID=nRqa0vX&amp;CVID=nRqa0vX&amp;CVID=nRqa0vX" rel="noopener noreferrer nofollow" target="_blank"><u>Health Products (Clinical Trials) Regulations 2016 (Version in force from 1 October 2021) – Allowing Qualified Pharmacist to Be Principal Investigators In Clinical Trials</u></a></strong>.&nbsp;</p>
<p><strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/c4565f5f-f052-4c3d-9884-e4673876581e/Additional_Info_Reg_Pharmacist_as_PI_HSA_CT_Guidance_FINAL_22Oct21.pdf?MOD=AJPERES&amp;CVID=nRlMK5a&amp;CVID=nRlMK5a&amp;CVID=nRlMK5a" rel="noopener noreferrer nofollow" target="_blank"><u>Additional Reading Info_Reg Pharmacist as PI HSA CT Guidance FINAL</u></a></strong>
</p>
<p>&nbsp;</p>
<p><strong><u>3. Amendments to the Requirements for Clinical Research Material Containing Codeine Cough Preparations</u></strong>
</p>
<p>MOH has worked with HSA to make amendments to the Health Products (Therapeutic)
Regulations (“TP Regs”) to change the supply limits for sale and supply
of codeine cough preparations. Consequential to the amendments to the TP
Regs, the <strong><a href="https://www.hsa.gov.sg/clinical-trials/overview" rel="noopener noreferrer nofollow" target="_blank"><u>HSA | Regulatory overview of clinical trials​</u></a></strong> has
been amended to:</p>
<p>• Remove the codeine supply restrictions for clinical research materials,
in view of the existing research governance frameworks in place to curb
the abuse of codeine in the context of clinical research studies; and</p>
<p>• Cover all dosage forms of codeine cough preparations, in the requirement
for export approval for consignments of codeine-containing clinical research
materials, to align with the requirements under the TP Regs.</p>
<p>Please contact HSA at <strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>HSA_CT@hsa.gov.sg</u></a></strong> should
you require any clarifications.</p>
<p>
<br><strong>IMPORTANT NOTICE: [HSA Clinical Trials] UPDATES ON THE IMPLEMENTATION OF THE CELL, TISSUE AND GENE THERAPY PRODUCTS FRAMEWORK (1 MAR 2021)</strong>
</p>
<p>
<br>The Health Sciences Authority (HSA) has introduced a new category of health
products to be regulated under the Health Products Act, namely, cell tissue
and gene therapy products (CTGTP). The new controls take effect on 1 March
2021.</p>
<p>
<br>The new and amended regulations i.e. the <strong>Health Products (Cell, Tissue and Gene Therapy) Regulations 2021, Health Products (Clinical Research Materials) Regulations 2021</strong> and <strong>Health Products (Clinical Trials) Regulations 2021</strong> can
be found the <strong><a href="https://sso.agc.gov.sg/" rel="noopener noreferrer nofollow" target="_blank"><u>Singapore Statues Online Website</u></a></strong>.</p>
<p>
<br>Click here for the <strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/5d5223f7-7b06-4ebe-8c2f-792a8e792251/REGULATIONS_1Mar21.zip?MOD=AJPERES&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K&amp;CVID=nx3ga9K" rel="noopener noreferrer nofollow" target="_blank"><u>zip</u></a></strong> file
of a consolidation of the Regulations.</p>
<ul data-tight="true" class="tight">
<li>
<p>Health Products (Cell, Tissue and Gene Therapy) Regulations 2021</p>
</li>
<li>
<p>Health Products (Clinical Research Materials) Regulations 2021</p>
</li>
<li>
<p>Health Products (Clinical Trials) Regulations 2021</p>
</li>
</ul>
<p>HSA had also updated their regulatory guidance. The following regulatory
guidance, which include more substantial updates are:-</p>
<ul data-tight="true" class="tight">
<li>
<p>Determination of whether a Clinical Trial requires Clinical Trial Authorisation
(CTA), Clinical Trial Notification (CTN) or Clinical Trial Certificate
(CTC)</p>
</li>
<li>
<p>Regulatory Requirements for New Applications and Subsequent Submissions</p>
</li>
<li>
<p>Clinical Research Materials</p>
</li>
<li>
<p>Labelling of Investigational and Auxiliary Products in Clinical Trials</p>
</li>
</ul>
<p>Where relevant, HSA had also taken the opportunity to provide more information
in the guidance to address common enquiries by Clinical Trial Stakeholders.&nbsp;
All clinical trial regulatory guidance may be found on <strong><a href="https://www.hsa.gov.sg/clinical-trials/regulatory-guidances" rel="noopener noreferrer nofollow" target="_blank"><u>HSA website</u></a></strong>.</p>
<p>
<br>Please contact HSA (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>HSA_CT@hsa.gov.sg</u></a></strong>)
should you require further clarifications to the above.</p>
<p>
<br>Disclaimer: Readers are advised to refer to Singapore Statues Online Website,
HSA website for the latest information related to Clinical Trials, regulations
and HSA Clinical Trial Regulatory Guidance.</p>
<p>&nbsp;</p>
<p><strong>IMPORTANT NOTICE: GUIDANCE ON ELECTRONIC CONSENT &amp; CRM NOTIFICATION NON-COMPLINANCE FORM (16 Dec 20)</strong>
</p>
<p>1. Guidance on Electronic Consent</p>
<p>The purpose of this document is to provide guidance to sponsors and investigators
on electronic consent (i.e. e-consent).</p>
<p>Click here to download the <strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/31cda5cc-ef5d-4707-81af-26fdc5bd1f00/hsa_ctb_guidance_e-consent_6nov2020.pdf?MOD=AJPERES&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu&amp;CVID=nrQoCZu" rel="noopener noreferrer nofollow" target="_blank"><u>HSA Clinical Trials Guidance – Electronic Consent</u></a></strong>.</p>
<p>A copy of the guidance is also available on the HSA website (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://www.hsa.gov.sg/clinical-trials/regulatory-guidance</u></a></strong>).</p>
<p>2. CRM Notification Non-Compliance Form via FormSG</p>
<p>The purpose of this form via FormSG (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://form.gov.sg/5f0fc43b9e6a4a0011f18fe0</u></a></strong>)
is for suppliers to notify HSA about non-compliances to applicable CRM
regulations relating to CRM notifications. Kindly refer to HSA website
(<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://www.hsa.gov.sg/clinical-trials/crm-notification</u></a></strong>)
for more information.</p>
<p>Please contact HSA (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>HSA_CT@hsa.gov.sg</u></a></strong>)
should you require further clarifications to the above.
<br>Disclaimer: Readers are advised to refer to HSA website for the latest
information related to Clinical Trials, regulations and HSA Guidance documents.</p>
<p>&nbsp;</p>
<p><strong>IMPORTANT NOTICE : HSA GUIDANCE ON THE CONDUCT OF CLINICAL TRIALS IN RELATION TO THE COVID-19 SITUATION (27 March 20)</strong>
</p>
<p>
<br>The Health Science Authority (HSA) has released a guidance to provide
general considerations to sponsors and investigators to ensure the safety
of trial participants, compliance with the clinical trials regulations
and ICH GCP (R2) Guidelines, and minimise risks to trial integrity, during
the Covid-19 Outbreak.</p>
<p>Click <strong><a href="https://www.research.nhg.com.sg/wps/wcm/connect/f3a55aa9-da29-4606-91bb-62d4418715c1/HSA+COVID19+Guidance+Clinical+Trials+27Mar2020.pdf?MOD=AJPERES&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do&amp;CVID=nfHz9Do" rel="noopener noreferrer nofollow" target="_blank"><u>here to download the HSA CTB COVID-19 Guidance for Clinical Trials</u></a></strong>
</p>
<p>A copy of the guidance is also available on the HSA website (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>https://www.hsa.gov.sg/clinical-trials/regulatory-guidance</u></a></strong>)</p>
<p>Please contact HSA (<strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>HSA_CT@hsa.gov.sg</u></a></strong>)
should you require further clarifications.</p>
<p>&nbsp;</p>
<p>&nbsp;<strong>Information and Resources</strong>
</p>
<p>&nbsp;</p>
<p>Researchers are advised to refer to the following resources for more information:
<br>&nbsp;</p>
<p><strong>HSA Websites on the Revised Regulatory Framework</strong>
</p>
<p>&nbsp;</p>
<ul data-tight="true" class="tight">
<li>
<p><strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Clinical_Trials/Overview/Regulatory_Framework.html</u></a></strong>
<a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank">
<br>
</a>&nbsp;</p>
</li>
<li>
<p><strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/therapeutic-productsportover.html</u></a></strong>
</p>
</li>
</ul>
<p>&nbsp;</p>
<p><strong>HSA Regulatory Guidances</strong>
<br>&nbsp;</p>
<ul data-tight="true" class="tight">
<li>
<p><strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Clinical_Trials/Overview/Regulatory_Guidelines.html</u></a></strong>
</p>
</li>
</ul>
<p>&nbsp;</p>
<p><strong>Legislation – Statutory Acts and Applicable Regulations</strong>
<br>&nbsp;</p>
<ul data-tight="true" class="tight">
<li>
<p><strong><a href="https://sso.agc.gov.sg/SL/HPA2007-S332-2016" rel="noopener noreferrer nofollow" target="_blank"><u>http://statutes.agc.gov.sg/aol/home.w3p</u></a></strong>
</p>
</li>
</ul>
<p></p>